Francisco Gimeno-Valiente
A5065811511- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- Colorectal Cancer Screening and Detection
- Lung Cancer Treatments and Mutations
- Helicobacter pylori-related gastroenterology studies
- Epigenetics and DNA Methylation
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Cancer-related gene regulation
- PI3K/AKT/mTOR signaling in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- RNA Research and Splicing
- Hippo pathway signaling and YAP/TAZ
- Cancer-related molecular mechanisms research
- Colorectal Cancer Surgical Treatments
- Gastrointestinal Tumor Research and Treatment
- T-cell and B-cell Immunology
- Peptidase Inhibition and Analysis
- Cholangiocarcinoma and Gallbladder Cancer Studies
CRUK Lung Cancer Centre of Excellence
2020-2025
University College London
2020-2025
London Cancer
2021-2025
Cancer Research UK
2020-2025
The London College
2022-2025
INCLIVA Health Research Institute
2017-2022
Universitat de València
2018-2022
The Francis Crick Institute
2022
Centro de Investigación Biomédica en Red de Cáncer
2021
Biomedical Research Institute
2019
BackgroundA high percentage of patients diagnosed with localized colon cancer (CC) will relapse after curative treatment. Although pathological staging currently guides our treatment decisions, there are no biomarkers determining minimal residual disease (MRD) and at risk being undertreated or even overtreated chemotherapy in this setting. Circulating-tumor DNA (ctDNA) can to be a useful tool better detect relapse.Patients methodsOne hundred fifty CC were prospectively enrolled study. Tumor...
Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions patient management stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored added benefits serial analysis: adjuvant chemotherapy (ACT) growth rates.We recruited 168 patients with treated curative intent at Danish Spanish hospitals between 2014 2019. To quantify in plasma samples...
Abstract B cells are frequently found in the margins of solid tumours as organized follicles ectopic lymphoid organs called tertiary structures (TLS) 1,2 . Although TLS have been to correlate with improved patient survival and response immune checkpoint blockade (ICB), underlying mechanisms this association remain elusive Here we investigate lung-resident cell responses patients from TRACERx 421 (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy) other lung cancer cohorts, a...
Abstract In this study, the impact of apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell (NSCLC) mouse models constrained tumorigenesis, while tumors treated with EGFR-targeted therapy associated treatment resistance. Analyses human NSCLC showed upregulation and revealed therapy-induced activation nuclear kappa (NF-κB) as an...
Abstract Recognition and elimination of pathogens cancer cells depend on the adaptive immune system. Thus, accurate quantification subsets is vital for precision medicine. We present lymphocyte estimation from nucleotide sequencing (ImmuneLENS), which estimates T cell B fractions, class switching clonotype diversity whole-genome data at depths as low 5× coverage. By applying ImmuneLENS to 100,000 Genomes Project, we identify genes enriched with somatic mutations in cell-rich tumors,...
Patient-derived organoids (PDOs) from advanced colorectal cancer (CRC) patients could be a key platform to predict drug response and discover new biomarkers. We aimed integrate PDO with multi-omics characterization beyond genomics.We generated 29 lines 22 CRC provided morphologic, genomic, transcriptomic characterization. performed sensitivity assays panel of both standard non-standard agents in five long-term cultures, integrated baseline proteomic by SWATH-MS RNA-seq analysis,...
Abstract Purpose: Despite the clinical advantage of combination trastuzumab and platinum-based chemotherapy in HER2-amplified tumors, resistance will eventually develop. The identification molecular mechanisms related to primary acquired is needed. Experimental Design: We generated lapatinib- trastuzumab-resistant clones deriving from two different gastric cancer cell lines. Molecular changes such as protein expression gene-expression profile were evaluated detect alterations that could be...
BackgroundColon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, such as plasma circulating tumour DNA (ctDNA), CDX2 staining, inflammation-associated cytokines and transcriptomic consensus molecular subtypes (CMS) classification, into multimodal approach may improve our accuracy in determining recurrence.MethodsOne hundred fifty...
Abstract Human tumors are diverse in their natural history and response to treatment, which part results from genetic transcriptomic heterogeneity. In clinical practice, single-site needle biopsies used sample this diversity, but cancer biomarkers may be confounded by spatiogenomic heterogeneity within individual tumors. Here we investigate clonally expressed genes as a solution the sampling bias problem analyzing multiregion whole-exome RNA sequencing data for 450 tumor regions 184 patients...
Abstract Background Chromosomal instability (CIN) is involved in about 70% of colorectal cancers (CRCs) and associated with poor prognosis drug resistance. From a clinical perspective, better knowledge these tumour’s biology will help to guide therapeutic strategies more effectively. Methods We used high-density chromosomal microarray analysis evaluate CIN level patient-derived organoids (PDOs) their original mCRC tissues. integrated the RNA-seq mass spectrometry-based proteomics data from...
Lung TRACERx is a prominent study employing multi-region and longitudinal multi-omics sequencing to unravel the evolutionary trajectories of cancer. While aberrant DNA methylation described in most cancers, its interplay with genomic alterations chromatin remodeling non-small cell lung cancer (NSCLC) less understood. We propose Allosteric Chromatin Activity Transition (AllChAT) as framework elucidate epigenetic dosage compensation mechanisms, focusing on essential genes impacted by...
Abstract Background Chromosomal instability (CIN) is pervasive during cancer evolution, particularly in non-small cell lung (NSCLC) where it associated with poor recurrence-free survival and correlates the frequency of whole genome doubling events (WGD). By duplicating complete set chromosomes, WGD a key event evolution prognosis targeted therapy resistance. Despite importance these events, genetic responsible for initiation maintenance CIN NSCLC have not been systematically investigated....
e15661 Background: CDX2 protein loss in colorectal cancer (CRC) correlates with poor prognosis, yet the mechanisms driving its and associated molecular alterations remain unclear. There is a pressing need for standardized methodologies to evaluate expression enhance patient stratification therapeutic decision-making. Methods: A 48-patient CRC cohort was analyzed using immunohistochemistry, as per Dalerba et al. To address limitations, we developed CODEX2 scoring system, integrating staining...
Abstract The finding of novel molecular markers for prediction or prognosis invasiveness in colorectal cancer (CRC) constitutes an appealing challenge. Here we show the up-regulation EPDR1 a prospective cohort 101 CRC patients, cDNA array 43 patients and silico analyses. encodes protein related to ependymins, family glycoproteins involved intercellular contacts. A thorough statistical model allowed us conclude that gene is significantly up-regulated tumour tissues when compared with normal...
In the setting of localized colon cancer (CC), circulating tumor DNA (ctDNA) monitoring in plasma has shown potential for detecting minimal residual disease (MRD) and predicting a higher risk recurrence. With tumor-only sequencing approach, however, germline variants may be misidentified as somatic variations, precluding possibility tracking up to 11% patients due lack known mutations. this study, we assess value adding white blood cells (WBCs) tissue enhance accuracy results.